Three Things You Need to Know: Understanding 5 Guiding Principles for a Medical Device PCCP
Understanding the FDA, HC, MHRA Joint Statement on 5 Guiding Principles for a Predetermined Change Control Plan for Medical Devices and Machine Learning
The U.S. Food and Drug Administration (FDA), Health Canada (HC), and the Medicines and Healthcare products Regulatory Agency (MHRA) have recently issued a joint statement outlining five guiding principles for a Predetermined Change Control Plan (PCCP) for medical devices and machine learning. In the ever-evolving landscape of healthcare and technology, the collaboration between regulatory bodies is crucial to ensure the safety and efficacy of medical devices, especially when they incorporate machine learning algorithms. Let’s delve into three key things you should know about this important development.
INSIGHT 1
The Growing Significance of Machine Learning in Medical Devices
Machine learning has become an integral part of modern medical devices, enhancing their capabilities for diagnosis, treatment, and patient care. These algorithms can adapt and improve over time, making it challenging for regulators to maintain oversight and ensure the continued safety and effectiveness of these devices. As machine learning technology continues to advance, it's critical to establish a framework for managing changes in these devices.
INSIGHT 2
The Five Guiding Principles
The joint statement from FDA, HC, and MHRA outlines five guiding principles that manufacturers of medical devices with machine learning components should follow in developing a predetermined change control plan:
-
Simply put, make sure the PCCP is developed within the bounds of your device’s intended use. Whether it excites you or terrifies you to think about the unlimited implications of AI, this joint statement from the world’s leading medical device authorities is establishing boundaries up front. For your AI/ML to remain within the confines of the device’s intended use, you must initiate a robust process that clearly establishes 1.) how much can your machine learn while still remaining within these limits, 2.) how are you going to verify, validate, or even stop those changes if necessary, and 3.) how does all of this affect your product? These considerations all need to fit within the focus of your PCCP.
-
Risk evaluation has always been a cornerstone of FDA’s approach to determining safety and efficacy so approach your PCCP from a risk-based perspective. Risk management is key to developing a safe device and your PCCP should be a part of that. Create a PCCP that maintains a risk-based perspective from concept to implementation and changes.
-
Evidence generated throughout the TPLC will focus on methods and metrics to prove benefits outweigh risks and such risks are properly mitigated and/or managed by your team
-
Give your users and stakeholders the full insight into the device before and after planned changes Manufacturers should maintain transparency in their change control processes and keep records of changes
-
Have a full grasp on the TPLC when creating your PCCP. Don’t just consider a plan that gets you through your design and development stages and regulatory approval, but consider the stakeholders and implications for post-market use when drafting the PCCP. We can’t plan for everything, but the more you can plan for, the better off you will be.description
The Impact on Medical Device Manufacturers
The FDA, HC, and MHRA's joint statement places a significant responsibility on medical device manufacturers, particularly those involved in the development of products with machine learning algorithms. Manufacturers will need to invest in comprehensive monitoring and data collection systems to support real-world performance assessments and demonstrate the safety and effectiveness of their devices.
Moreover, collaboration and open communication between manufacturers and regulatory agencies will be key to aligning on changes and ensuring that devices continue to meet safety and efficacy standards.
Conclusion
The joint statement from the FDA, HC, and MHRA on the five guiding principles for a predetermined change control plan for medical devices and machine learning represents a pivotal development in the regulation of these innovative technologies. It emphasizes the importance of transparency, communication, and adaptability in a rapidly evolving field. Medical device manufacturers must embrace these principles to navigate the changing regulatory landscape successfully, ultimately contributing to safer and more effective medical devices for the benefit of patients and healthcare providers worldwide.
About Medtech Impact Partners | Talk to the FDA before you talk to the FDA™
MedTech Impact Partners is a leader in regulatory strategy and support. Built on decades of government and private sector experience, our services position clients to get innovative health technologies to market faster.
Our team of consultants guide MedTech companies over regulatory hurdles at the FDA, helping them deliver on key milestones and protect their bottom line. MIP’s customized approach and suite of services focus on developing sound regulatory strategy, diligent review, and managing risks for clients.
Need regulatory support? Our team is scheduling discovery meetings to learn more about your organization and goals. If you’re interested in learning more, please contact us.